Introduction: In recent decades, biologics have resulted in significantly improved medical management of ulcerative colitis (UC). Rates of surgery for UC are declining. However, there is still a controversial question of the relation of biologics to postoperative adverse outcomes and the most ...
Heparin has anti-inflammatory and immunomodulatory activity which may be of therapeutic benefit in the treatment of ulcerative colitis.To test whether low molecular weight heparin, given subcutaneously, would provide a significant therapeutic response compared with placebo in the treatment of mild to moder...
Safety analyses were performed up to the cutoff date of the week-52 analysis (Measure Up 1, December 21, 2020; Measure Up 2, January 15, 2021). The safety population included all patients in the main study who received at least 1 dose of study drug. Efficacy and safety analyses were ...
FDA approval history for Rinvoq (upadacitinib) used to treat Rheumatoid Arthritis, Psoriatic Arthritis, Atopic Dermatitis, Ulcerative Colitis, Crohn's Disease, Ankylosing Spondylitis, Non-Radiographic Axial Spondyloarthritis. Supplied by AbbVie Inc.
No notable adverse reactions have been reported to date. CONCLUSION Our case report suggests that upadacitinib may represent a valuable strategy for treating refractory UC with primary nonresponse. Key Words: Upadacitinib; Refractory ulcerative colitis; Primary nonresponse; Infliximab; Vedolizumab; Case...
I was diagnosed with Ulcerative Colitis in June of 2010. What do you remember most about that day? Looking back, if you could tell yourself one thing about the diagnosis you were about to receive, what would it be? I remember waking up from the colonoscopy and having my mom in the reco...
Journal of Crohn's and Colitis, 2023, 17, 338–351 https://doi.org/10.1093/ecco-jcc/jjac141 Advance access publication 17 September 2022 Original Article Tofacitinib for the Treatment of Ulcerative Colitis: An Integrated Summary of up to 7.8 Years of Safety Data fro...
However, to date no evidence exists on whether managing pre-syncope patients the same as syncope patients improves outcomes. As such, future studies are needed to further explore which patients with pre-syncope are at higher risk for adverse outcomes, with the ultimate goal to derive and ...
As sustained inflammation is known to produce an upregulation of central CRF [57,58,59], it seems plausible that this could result in a suppression of AEA signaling that in turn could contribute to the development of comorbid anxiety in colitis. To further examine the relationship between eCBs...
- 《Crohns & Colitis》 被引量: 0发表: 2022年 Microbiota, dietary fibre, and gastrointestinal health: Providing up-to-date diet information to patients with Crohn's disease: P-7 The effect of dietary fibre on colonic microbiota is an emerging concept. Yet, not all gastroenterology professionals...